Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3368715 in Advanced Solid Tumors and DLBCL
NCT03666988Phase 1Terminated
- Sponsor
- GSK
- Start
- Oct 2018
- Primary completion
- Mar 2021
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of GSK3368715 in solid tumor, diffuse large B-cell lymphoma (DLBCL), pancreatic cancer (PC) and 2 more (5 arms), sponsored by GSK. Primary endpoints: Number of Participants With Dose Limiting Toxicities up to 21 days, Number of Participants With Non-Serious Adverse Events (Non-SAEs) and SAEs up to 28 months and 2 more. Started Oct 2018; status: terminated.
02
Drugs
GSK3368715
03
Conditions
solid tumordiffuse large B-cell lymphoma (DLBCL)pancreatic cancer (PC)non-small cell lung cancer (NSCLC)bladder cancer
Beyond the preview
Go deeper on NCT03666988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03666988.